ABIRATERONE TARBIS 250 mg FILM-COATED TABLETS

Introduction

Package Leaflet: Information for the User

Abiraterone Tarbis 250 mg film-coated tablets EFG

abiraterone acetate

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

1. What is Abiraterone Tarbis and what is it used for
2. What you need to know before you take Abiraterone Tarbis
3. How to take Abiraterone Tarbis
4. Possible side effects
5. Storage of Abiraterone Tarbis
6. Contents of the pack and other information

1. What is Abiraterone Tarbis and what is it used for

Abiraterone Tarbis contains the active substance abiraterone acetate. It is used for the treatment of prostate cancer in adult men that has spread to other parts of the body. Abiraterone works by stopping your body from making testosterone; this can slow down the growth of your prostate cancer.

When Abiraterone Tarbis is prescribed in the early stages of the disease and you are still responding to hormone treatment, it is used together with a treatment to lower your testosterone levels (androgen deprivation therapy).

When you take this medicine, your doctor will also prescribe another medicine called prednisone or prednisolone to reduce the risk of high blood pressure, fluid retention, or low potassium levels in your blood.

2. What you need to know before you take Abiraterone Tarbis

Do not take Abiraterone Tarbis

• if you are allergic to abiraterone acetate or any of the other ingredients of this medicine (listed in section 6).
• if you are a woman, especially if you are pregnant. Abiraterone Tarbis is only for use in male patients.
• if you have severe liver disease.
• in combination with Ra-223 (which is used to treat prostate cancer).

Do not take this medicine if any of the above applies to you. If you are not sure, consult your doctor or pharmacist before taking this medicine.

Warnings and precautions

Talk to your doctor or pharmacist before you start taking this medicine:

• if you have liver problems,
• if you have been told you have high blood pressure or heart failure or low potassium levels in your blood (low potassium levels in your blood can increase your risk of heart rhythm problems),
• if you have had other heart or blood vessel problems,
• if you have a fast or irregular heart beat,
• if you have difficulty breathing,
• if you have gained weight quickly,
• if you have swelling in your feet, ankles, or legs,
• if you have taken ketoconazole in the past for prostate cancer,
• about the need to take this medicine with prednisone or prednisolone,
• about possible side effects on your bones,
• if you have high blood sugar levels.

Tell your doctor if you have been told you have any heart or blood vessel problems, including heart rhythm problems (arrhythmia), or if you are being treated with medicines for these problems.

Tell your doctor if you have yellowing of the skin or eyes, dark urine, or severe nausea or vomiting, as these can be signs of liver problems. Rarely, liver failure (acute hepatic failure) can occur, which can be life-threatening.

A decrease in red blood cell count, reduced sexual desire, and cases of muscle weakness and/or muscle pain may occur.

Abiraterone Tarbis must not be taken in combination with Ra-223 due to a possible increased risk of bone fractures or death.

If you plan to take Ra-223 after treatment with abiraterone and prednisone/prednisolone, you must wait 5 days before starting Ra-223 treatment.

If you are not sure if any of the above applies to you, consult your doctor or pharmacist before taking this medicine.

Blood tests

Abiraterone Tarbis may affect your liver even if you do not have any symptoms. While you are taking this medicine, your doctor will regularly perform blood tests to check for any effects on your liver.

Children and adolescents

This medicine must not be used in children or adolescents. If a child or adolescent accidentally ingests abiraterone, they should go to the hospital immediately and bring this leaflet with them to show to the emergency doctor.

Other medicines and Abiraterone Tarbis

Consult your doctor or pharmacist before taking any other medicine.

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This is important because abiraterone may increase the effects of certain medicines, including heart medicines, sedatives, some diabetes medicines, herbal medicines (e.g., St. John's Wort), and others. Your doctor may consider changing the dose of these medicines. Additionally, some medicines may increase or decrease the effects of abiraterone. This may lead to side effects or abiraterone not working as well as it should.

Androgen deprivation therapy may increase the risk of heart rhythm problems. Tell your doctor if you are being treated with medicines used to treat heart rhythm problems (e.g., quinidine, procainamide, amiodarone, and sotalol); or medicines that increase the risk of heart rhythm problems [e.g., methadone (used for pain relief and as part of drug addiction detoxification), moxifloxacin (an antibiotic), antipsychotics (used for severe mental illnesses)].

Consult your doctor if you are taking any of the medicines listed above.

Abiraterone Tarbis with food

• This medicine must not be taken with food (see section 3, "How to take Abiraterone Tarbis")
• Taking abiraterone with food may cause side effects.

Pregnancy and breastfeeding

Abiraterone Tarbis is not indicated in women.

• This medicine may harm the fetus if taken by a pregnant woman.
• Pregnant or potentially pregnant women should wear gloves if they need to touch or handle abiraterone.
• If you have sex with a woman of childbearing age, you should use a condom and another effective method of birth control.
• If you have sex with a pregnant woman, you should use a condom to protect the fetus.

Driving and using machines

It is unlikely that this medicine will affect your ability to drive or use tools or machines.

Abiraterone Tarbis contains lactose

Abiraterone Tarbis contains lactose (a type of sugar). If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.

Abiraterone Tarbis contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per film-coated tablet; this is essentially "sodium-free".

3. How to take Abiraterone Tarbis

Follow the instructions for administration of this medicine exactly as told by your doctor. If you are unsure, consult your doctor or pharmacist again.

How much to take

The recommended dose is 1,000 mg (four 250 mg tablets) once a day.

How to take this medicine

• Take this medicine by mouth.
• Do not take this medicine with food. Taking abiraterone with food may cause your body to absorb more medicine than necessary, which can cause side effects.
• Take the abiraterone tablets as a single dose once a day on an empty stomach. Abiraterone Tarbis should be taken at least 2 hours after eating and no food should be consumed for at least 1 hour after taking abiraterone (see section 2, "Abiraterone Tarbis with food"). Swallow the tablets whole with water.
• Do not break the tablets.
• Abiraterone Tarbis is given together with a medicine called prednisone or prednisolone. Take prednisone or prednisolone exactly as your doctor tells you.
• You will need to take prednisone or prednisolone every day while you are taking abiraterone.
• If you have a medical emergency, you may need to adjust the amount of prednisone or prednisolone you take. Your doctor will tell you if you need to change the dose of prednisone or prednisolone. Do not stop taking prednisone or prednisolone unless your doctor tells you to.

Your doctor may also prescribe other medicines while you are taking abiraterone and prednisone or prednisolone.

If you take more Abiraterone Tarbis than you should

If you take more than you should, talk to your doctor or go to the hospital immediately.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount taken.

If you forget to take Abiraterone Tarbis

• If you forget to take abiraterone or prednisone or prednisolone, take your normal dose the next day.
• If you forget to take abiraterone or prednisone or prednisolone for more than one day, consult your doctor immediately.

If you stop taking Abiraterone Tarbis

Do not stop taking abiraterone or prednisone or prednisolone unless your doctor tells you to.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Stop taking Abiraterone Tarbis and see a doctor immediately if you experience any of the following:

• Muscle weakness, muscle contractions, or rapid heart beat (palpitations). These can be signs of low potassium levels in your blood.

Other side effects are:

Very common(may affect more than 1 in 10 people):

Fluid retention in the legs or feet, low potassium levels in the blood, elevated liver function tests, high blood pressure, urinary tract infection, diarrhea.

Common(may affect up to 1 in 10 people):

High levels of fats in the blood, chest pain, irregular heart beat (atrial fibrillation), heart failure, fast heart rate, severe infections (sepsis), bone fractures, indigestion, blood in the urine, skin rash.

Uncommon(may affect up to 1 in 100 people):

Problems with the adrenal glands (related to problems with salt and water), abnormal heart rhythm (arrhythmia), muscle weakness and/or muscle pain.

Rare(may affect up to 1 in 1,000 people):

Lung irritation (also called allergic alveolitis).

Liver failure (also called acute hepatic failure).

Frequency not known(cannot be estimated from the available data):

Heart attack, changes in the electrocardiogram (ECG) (prolonged QT), and severe allergic reactions with difficulty swallowing or breathing, face, lips, tongue, or throat swelling, or itchy rash.

Bone density loss may occur in men receiving treatment for prostate cancer. Abiraterone in combination with prednisone or prednisolone may increase this bone density loss.

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es.

By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Abiraterone Tarbis

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister or bottle. The expiry date is the last day of the month stated.

This medicine does not require any special storage conditions.

HDPE bottle (after opening): use within 60 days.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Contents of the pack and other information

Composition of Abiraterone Tarbis

The active substance is abiraterone acetate.

Each film-coated tablet contains 250 mg of abiraterone acetate.

Tablet core: lactose monohydrate, croscarmellose sodium, hypromellose 2910 (E464), sodium lauryl sulfate, silicified microcrystalline cellulose (silica colloidal anhydrous and microcrystalline cellulose), silica colloidal anhydrous, magnesium stearate.

Coating material: partially hydrolyzed polyvinyl alcohol (E1203), titanium dioxide (E171), macrogol (E1521), talc (E553b).

Appearance and packaging

White, oval-shaped, film-coated tablets with "H" on one side and "A1" on the other side, free from physical defects. (Dimensions: 14.60 mm x 8.60 mm).

Al-Al blister packs containing 120 film-coated tablets in a blister pack with 120 x 1 film-coated tablet units.

HDPE bottle:

120 film-coated tablets.

Not all pack sizes may be marketed.

Marketing authorization holder

Tarbis Farma S.L.

Gran Vía Carlos III, 94

08028 Barcelona

Spain

Manufacturer

Amarox Pharma B.V.

Rouboslaan 32

Voorschoten, 2252TR

Netherlands

This medicine is authorized in the Member States of the European Economic Area under the following names:

Germany: Abirateron Amarox 250 mg film-coated tablets

Netherlands: Abirateron Amarox 250 mg filmomhulde tabletten

Spain: Abiraterona Tarbis 250 mg film-coated tablets EFG

Date of last revision of this leaflet: December 2022

Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) www.aemps.gob.es/